Left adrenal aldosteronism coexisting with left paraaortic paraganglioma presenting as bilateral adrenal and left paraaortic tumors—comprehensive adrenal evaluation aiding perfect management: a case report

Yu-Chen Hsu¹, Cheng-Han Lee², Chen-Yu Chen² and Chung-Jye Hung²*  

Abstract

Background: Coexistence of a catecholamine-secreting tumor and an adrenal cortical tumor is quite rare which makes both diagnosis and management challenging. The purpose of this article is to describe the presence of this condition, share a stepwise approach for preoperative evaluation, and review the related literature.

Case presentation: A 44-year-old male patient had a history of hypertension and aggravating hypokalemia for years. Abdominal computed tomography incidentally found concomitant bilateral adrenal and left para-aortic tumors. Comprehensive adrenal hormone tests revealed a high aldosterone-renin ratio and mildly elevated 24-h urine vanillylmandelic acid and norepinephrine levels. Subsequently, a metaiodobenzylguanidine scan showed uptake over the left para-aortic tumor, and NP-59 adrenal scintigraphy showed uptake over the left adrenal tumor. Further confirmatory tests, including captopril suppression, irbesartan suppression, and saline infusion, all confirmed the diagnosis of hyperaldosteronism. Adrenal venous sampling following 2 months of preparation with an alpha blocker demonstrated a left aldosterone-producing adrenal adenoma. Combining hormonal analysis, imaging studies, and adrenal venous sampling, the patient was diagnosed with left adrenal aldosteronoma, right adrenal nonfunctional tumor, and left para-aortic paraganglioma (PGL). Accordingly, laparoscopic left adrenalectomy and left PGL excision were performed smoothly under alpha blocker maintenance. The pathology report confirmed left adrenal cortical adenoma and left para-aortic PGL. Postoperatively, the blood pressure, biochemical tests, and adrenal hormone assays returned to normal, and related symptoms disappeared and were relatively stable during the follow-up period of two years.

Conclusions: This is the first case of left para-aortic PGL coexisting with an ipsilateral aldosterone-producing adenoma presenting as a left para-aortic tumor associated with bilateral adrenal tumors. Awareness of the rarity of this coexistence can avoid unexpected disasters during the process of evaluation and management.

Keywords: Paraganglioma, Hyperaldosteronism, Metaiodobenzylguanidine scan, Adrenal venous sampling, Case report

Background

Among all hypertensive patients, primary hyperaldosteronism is frequently diagnosed with a prevalence varying from 3.2% to 12.7% in primary care [1]. Unilateral
The coexistence of catecholamine-secreting tumors and adrenal cortical tumors is quite rare and leads to not only diagnosis but also management challenges. Here, a case of para-aortic PGL coexisting with an ipsilateral aldosterone-producing adenoma is reviewed.

**Case presentation**

A 44-year-old male patient presented with years of hypertension (since 2012) and received regular follow-up and medical treatment at a cardiovascular outpatient clinic. Some nonspecific symptoms, including chest tightness, palpitations, flushing, and bilateral leg weakness, were described. Neither headache nor sweating was complained. According to the guidelines from the National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure [17], indications for evaluation of secondary hypertension include resistant hypertension, age of onset before puberty, age younger than 30 years with nonobesity and no family history, malignant hypertension, or acute rise of blood pressure in previous stable readings. Therefore, a more detailed assessment of the possible underlying cause of the hypertension was not done between 2012–2016. It was not until 2016 that hypokalemia was first noted. From 2016 to 2019, there were episodes of recurrent hypokalemia despite potassium supplementation. The potassium level was approximately 3.1 mmol/L (normal, 3.5–5.1 mmol/L) with a high potassium diet during 2016–2018 but decreased to 2.7 mmol/L in 2018. Hypokalemia-associated drugs, such as thiazide diuretics, were then discontinued. However, the potassium level dropped to 2.3 mmol/L in 2019, and intravenous potassium supplementation was given twice. To investigate the cause of hypokalemia, several blood and urinary examinations were performed. A trans-tubular potassium gradient of 10.5 (>7) and urine potassium/creatinine ratio of 68 (>1.5) indicated renal loss of potassium. Venous gas analysis reported metabolic alkalosis, which ruled out renal tubular acidosis or other causes of metabolic acidosis. Given renal potassium loss accompanied by refractory hypertension, hyperaldosteronism was therefore suspected. Elevated plasma aldosterone levels of 489 pg/ml (normal, 68.0–173.0 pg/ml), low plasma renin concentrations of 2.89 pg/ml (normal, 1.1–20.2 pg/ml), and elevated aldosterone-renin ratios (ARRs) of 169.2 were strongly indicated primary aldosteronism.

Further abdominal computed tomography incidentally found bilateral adrenal tumors (right: 1.2 cm, left: 2.1 cm) and a left para-aortic tumor (4.3 cm), with the Hounsfield unit of the para-aortic tumor being approximately 40 under the noncontrast phase and 70 under the arterial phase, which suggested many possibilities (Fig. 1). Upon referral to the surgical outpatient clinic, his blood pressure was approximately 155/105 mmHg with receiving three types of antihypertensives, including calcium channel blocker/angiotensin receptor blocker (amlodipine/
valsartan (5/80 mg) 1# bid, nifedipine (10 mg) 1# prn) and an alpha blocker (doxazosin (4 mg) 1# qd). Reviewing his family history, no endocrine disorders were identified. To clarify the nature of the bilateral adrenal tumors, comprehensive adrenal hormone tests were performed, including serum cortisol, adrenocorticotropic hormone (ACTH), 1 mg overnight dexamethasone suppression test (ODST), dehydroepiandrosterone (DHEA), and 24-h urine vanillylmandelic acid (VMA) and catecholamines. The results showed normal cortisol levels of 12.6 µg/dl (normal, 2.9–17.3 µg/dl), ACTH levels of 34.5 pg/ml (normal, 7.2–63.3 pg/ml), DHEA levels of 1464 ng/ml (normal, 215–2769 ng/ml), suppressive ODST tests of cortisol levels < 1 µg/dl (normal, < 1.8 µg/dl), mildly elevated 24-h urine VMA levels of 8.61 mg/day (normal, 1–7.5 mg/day), norepinephrine levels of 105.0 µg/day (normal, 12.1–85.5 µg/day), and normal epinephrine levels of 16.5 µg/day (normal, 0–22.4 µg/day). Metanephrine and normetanephrine were not available in our lab. Mild elevation of 24-h urine VMA and catecholamines suggested more possibilities for both adrenal and para-aortic lesions that could be para-aortic PGL, unilateral or bilateral pheochromocytoma (although less likely), or neither.

To verify the hormonal function results, a MIBG scan was performed that revealed high uptake over the left para-aortic but not the bilateral adrenal tumors, indicating the diagnosis of left para-aortic PGL (Fig. 2). For suspicion of primary hyperaldosteronism, confirmatory tests, including captopril suppression, irbesartan suppression, and saline infusion were performed, and all confirmed the diagnosis. Briefly, the captopril suppression test showed a non-suppressed aldosterone level (645 pg/ml) and ARR (507) after giving 50 mg captopril for 1.5 h (a positive test is defined as aldosterone level > 100 pg/ml and ARR > 35). The irbesartan suppression test showed a non-suppressed aldosterone level (590 pg/ml) and ARR (479) after giving 75 mg irbesartan for 2 h (a positive test is defined as aldosterone level > 100 pg/ml and ARR > 35). The saline infusion test showed a non-suppressed aldosterone level (540 pg/ml) after 2 L of intravenous saline infusion for 4 h (a positive test is defined as an aldosterone level > 100 pg/ml) (Table 1). The posture stimulation test showed a mild reduction in serum aldosterone (337 pg/ml to 302 pg/ml) after 4 h of ambulation. Subsequently, NP-59 adrenal scintigraphy revealed radiotracer accumulation over the left suprarenal region, which proved left adrenal functioning cortical adenoma (Fig. 2). For definite lateralization, adrenal venous sampling (AVS) was performed after 2 months of alpha blocker preparation (doxazosin (4 mg) shifted to terazosin (2 mg), terazosin dose titration from 0.5# to 3# hs) accompanied with calcium channel blocker/angiotensin receptor blocker (amlodipine/valsartan (5/80 mg) 1# bid, nifedipine (10 mg) 1# prn). The blood pressure before AVS was approximately 140/95 mmHg and jumped to 170/110 mmHg during the procedure in the short term. Left aldosterone-producing adrenal adenoma was confirmed by AVS data analysis (Table 2). A potassium-sparing diuretic (spironolactone (25 mg) 1# bid) was added following AVS with maintenance of the calcium channel blocker/angiotensin receptor blocker (amlodipine/valsartan (5/80 mg) 1# bid) and an alpha blocker (terazosin
Combining hormonal analysis, imaging studies, and adrenal venous sampling, the patient was diagnosed with left adrenal aldosteronoma, right adrenal nonfunctional tumor, and left para-aortic PGL. Accordingly, laparoscopic left adrenalectomy followed by para-aortic PGL excision were performed under the use of antihypertensives (spironolactone (25 mg) 1# bid, amlodipine/valsartan (5/80 mg) 1# bid, and terazosin (2 mg) 3# hs) with a preoperative blood pressure of approximately 130/90 mmHg. Operative findings showed one 2.4*2.0*2.0 cm soft homogenous yellowish

![Metaiodobenzylguanidine scan](image)

**Fig. 2** Metaiodobenzylguanidine scan (a) showed uptake over the left para-aortic tumor, which favored paraganglioma, and NP-59 adrenal scintigraphy (b) showed mild radiotracer accumulation over the left supra-renal region, which favored left adrenal functional cortical tumor.

| Table 1 | Confirmatory test for hyperaldosteronism |
|---|---|
| | Cortisol (µg/dl) | K (mmol/L) | PRC (pg/ml) | Aldosterone (pg/ml) |
| Captopril suppression test (50 mg) | | | | |
| Before | 1.58 | 654 | | |
| 1 h later | 2.10 | 749 | | |
| 1.5 h later | 1.27 | 645 | | |
| Irbesartan suppression test (75 mg) | | | | |
| Before | 2.60 | 810 | | |
| 2 h later | 1.23 | 590 | | |
| Saline infusion test (2 L) | | | | |
| Before | 10.9 | 2.5 | 1.81 | 627 |
| 4 h later | 7.86 | 2.9 | < 1.0 | 540 |

**Table 2** Adrenal venous sampling result

| AVS | IVC | Right | Left |
|---|---|---|---|
| **Pre-ACTH stimulation** | | | |
| Aldosterone (pg/ml) | 1036/1080 | 676/625 | 9219/9319 |
| Cortisol (µg/dl) | 13.80/13.70 | 19.10/18.90 | 47.36/43 |
| Aldosterone/Cortisol | 75.07/78.83 | 35.39/33.07 | 194.90/216.72 |
| Selectivity index | 1.38/1.38* | 3.43/3.14 | |
| Relative secretion index | 0.47/0.42 | 2.60/2.75 | |
| Lateralization index | 5.11/6.55 | | |
| Contralateral suppression index | 0.47/0.42 | | |
| **Post-ACTH stimulation** | | | |
| Aldosterone (pg/ml) | 1418/1222 | 6252/5719 | 12,388/19962 |
| Cortisol (µg/dl) | 17.90/18.30 | 937/968 | 346/506 |
| Aldosterone/Cortisol | 79.22/66.78 | 6.67/5.91 | 35.8/39.45 |
| Selectivity index | 52.35/52.90 | 19.32/27.65 | |
| Relative secretion index | 0.08/0.09 | 0.45/0.59 | |
| Lateralization index | 5.63/6.56 | | |
| Contralateral suppression index | 0.08/0.09 | | |

**AVS** Adrenal venous sampling, IVC Inferior vena cava, ACTH Adrenal corticotrophic hormone, Selectivity index (Cortisol/ACTH), Relative secretion index (Aldosterone/Cortisol), Lateralization index (Aldosterone/Cortisol), Contralateral suppression index (Aldosterone/Cortisol).

*Adrenal venous sampling was done twice before and after ACTH stimulation and revealed left lateralization by lateralization index and contralateral suppression index.

*Successful catheterization confirmed except pre-ACTH stimulation right adrenal vein sampling (positive cutoff value > 2x).
left adrenal cortical tumor and one 4.5*4.5*2.2 cm para-aortic flesh tumor surrounded by renal vessels, the aorta, celiac trunk, and superior mesenteric artery (Fig. 3). Hyperglycemia (>500 mg/dl), metabolic acidosis, and systolic blood pressure elevation to 160 mmHg occurred during manipulation of the para-aortic PGL, and systolic blood pressure dropped to approximately 80 mmHg after removal of the para-aortic PGL. The patient was sent to the intensive care unit for postoperative care. Hyperglycemia and metabolic acidosis were controlled with insulin and intravenous fluid supplementation. Extubation was successful on the 2nd postoperative day, and hypokalemia was corrected in two days. The patient was then transferred to the general ward with a stable condition on the third postoperative day.

The final pathology revealed adrenal cortical adenoma and para-aortic PGL with rare mitotic figures and absent necrosis. Furthermore, endocrine function evaluations were performed for the potential related components of multiple endocrine neoplasia, including calcitonin, carcinoembryonic antigen, calcium, phosphorus, parathyroid hormone, growth hormone, and prolactin, which were all normal. Sonography reported no identified thyroid or parathyroid lesions. Genetic testing, including ARNT (HIF1β), ATRX, BRAF, CSDE1, EGLN1 (PHD2), EPAS1 (HIF1α), FGFR1, HRAS, IDH1, MAML3, MAX, NF1, NGFR, RET, SDHA, SDHAF2, SDHB, SDHC, SDHD, SETD2, TMEM127, TP53, VHL, CDKN2A, H3F3A, IDH2, KMT2D, MDH2C, MERTK, and MET, using next-generation sequencing revealed no major genetic variants, although gene variants related to large genome insertion, large genome deletion, inversion, and complicated rearrangement may not be totally excluded.

His blood pressure returned to approximately 120/85 mmHg with all the antihypertensive drugs being withdrawn three months after the operation. Urine VMA, catecholamine profile, and serum aldosterone, renin, and potassium levels returned to normal quickly postoperatively and have remained relatively stable. The patient had no symptoms of bilateral leg weakness, chest tightness, or palpitations during the follow-up period of two years.

Discussion and conclusions
The coexistence of catecholamine-secreting tumors and adrenal cortical tumors is extremely rare and the manifestation of this combination requires further description. Regarding this combination, catecholamine-secreting tumors can be either pheochromocytomas or PGLs, and adrenal cortical tumors can be aldosterone-secreting, Cushing or subclinical Cushing tumors, hyperandrogenic, or nonfunctioning tumors. Regarding manifestation, the coexistence of catecholamine-secreting tumors and adrenal cortical tumors can manifest as ipsilateral or contralateral tumors, and each tumor can manifest as unilateral or bilateral. From the literature reported after 1985, there were 38 cases of pheochromocytoma coexisting with adrenal cortical tumors, including 13 cases of hyperaldosteronism [18–25], 8 cases of Cushing’s or subclinical Cushing’s tumors [14, 18, 26–28], 1 case of hyperandrogenism [29], 6 cases of nonfunctioning adrenal tumors [30–34], and 10 cases of unknown functional entities [18, 35]. Furthermore, there have been only 4 cases of PGL coexisting with unilateral adrenal cortical tumor, including 3 cases of hyperaldosteronism [23, 36, 37] and one case of adrenal cortical carcinoma [38]. The case presented is of a left aldosterone-producing adenoma coexisting with ipsilateral para-aortic PGL manifesting as bilateral adrenal tumors associated with a left para-aortic tumor. To our knowledge, this is the

Fig. 3 Operative findings showed (a) a 4.5*4.5*2.2 cm soft left para-aortic flesh tumor and (b) a 2.4*2.0*2.0 cm soft homogeneous yellowish left adrenal cortical tumor.
first case of this manifestation of combination following a thorough literature review. Some hypotheses have been proposed to explain the coexistence of catecholamine-secreting tumors and adrenal cortical tumors [14, 36, 39]; however, no consistent association was found by earlier research [40]. Therefore, most of the cases are still thought to be of coincidental coexistence.

The key point regarding the appropriate management of this complicated case is the challenging stepwise diagnostic approach, including the confirmation of the suspicious PGL that can mimic many presentations and the distinction between bilateral adrenal hyperplasia and unilateral aldosterone-producing adenoma—both being difficult to diagnose. Following initial hormonal screening studies, primary hyperaldosteronism was highly suspected; however, the evidence for the possible existence of a catecholamine-secreting tumor was not strong enough due to mild elevation of VMA and norepinephrine (lower than the twofold reference range). Based on the Mayo Clinic, the diagnostic cutoff point for pheochromocytoma is approximately twofold higher than the normal population reference range. Nevertheless, individuals with only mild or borderline elevations of urinary total metanephrines or catecholamines are not inappropriately labeled as potentially having a pheochromocytoma [41]. The study from Yu et al. supported the use of a 2-cell upper limit of normal as a value above which pheochromocytoma is likely; however, mildly elevated or normal results were 20% or 5% in the correctly diagnosed group and 17% or 17% in the underdiagnosed group, respectively [42]. The imaging phenotype consistent with pheochromocytoma includes enhancement with contrast medium on CT, high signal intensity on T2-weighted MRI, cystic and hemorrhagic changes, variable sizes, and the possibility of bilateral tumors [43–46]. The most common site of PGL is over the organ of Zuckernagl, between the inferior mesenteric artery and aortic bifurcation, the infradiaphragmatic paracolic region, and the mediastinum [47]. From the imaging phenotype of the paraaortic tumor in our case, catecholamine-secreting tumors were also taken into consideration despite having many differential diagnoses, including metastatic tumors, lymphadenopathy, or other mesenchymal tumors. Under these considerations, although the coexistence of PGL and adrenal cortical adenoma is extremely rare, an MIBG scan was prompted and excitingly became the determining factor in examination of this patient.

Second, the potential risk during the evaluation process for primary aldosteronism in the presence of a catecholamine-secreting tumor, in contrast to its absence, needs to be addressed in this particular setting. PGL is a catecholamine-secreting tumor that can result in cardiac arrest, respiratory failure, or other associated diseases if treated incautiously [42]. Therefore, there were several treatment suggestions regarding preoperative preparation before PGL removal, and the setting of blood pressure and heart rate before the operation was also being researched [7, 48]. Noxious stimuli, such as venous catheterization, tracheal intubation, skin incision, anesthetic drugs, and palpation of the tumor or abdominal exploration, can induce a hypertensive crisis by releasing catecholamines from the tumors [49]. Adrenal venous sampling is a vital procedure, although invasive, for the differential diagnosis of unilateral and bilateral hyperaldosteronism. The issue of the necessity of alpha blocker preparation before adrenal venous sampling should be taken into serious consideration in the existence of catecholamine-secreting tumors. However, these are still extremely rare suggestions about alpha blocker preparation for invasive procedures other than surgery on patients with catecholamine-secreting tumors, not to mention adrenal venous sampling. A newly published report recommended that diagnosis of concomitant pheochromocytoma and primary aldosteronism warrants adrenal venous sampling to determine the laterality of primary aldosteronism but also failed to address the necessity of alpha blocker preparation [25]. Hasassri et al. reported that two patients with primary aldosteronism developed a hypertensive crisis during adrenal venous sampling because of lack of awareness of the coexistence of a pheochromocytoma. They suggested that in patients with mixed biochemical and/or imaging findings, adrenal venous sampling should only be conducted after a pheochromocytoma has been excluded by biochemical workup to avoid a hypertensive crisis during the procedure [18]. This report clarifies and confirms our doubt about the necessity of preparation before adrenal venous sampling in this rare setting. In our case, an alpha blocker was added, accompanied with calcium channel blocker/angiotensin receptor blocker, once the MIBG report came out, and used for approximately two months before adrenal venous sampling was done. As expected, adrenal venous sampling was performed smoothly with successful catheterization.

Lastly, there are many debates regarding the necessity and number of positive confirmatory tests needed for primary aldosteronism evaluation. Various confirmatory tests may differ in terms of sensitivity, specificity, and reliability, and the choice of confirmatory test is commonly determined by considering cost, patient compliance, laboratory routine, and local expertise [7]. The European Endocrine Society guidelines recommend that patients with a positive ARR undergo one or more confirmatory tests to definitively confirm or exclude the diagnosis and also suggest that there may be no need for further confirmatory testing in...
the setting of spontaneous hypokalemia, plasma renin below detection levels plus plasma aldosterone levels higher than 20 ng/dl (200 pg/ml) [7]. Therefore, in our scenario, 1 confirmatory test should be enough in daily practice and the reason to do more confirmatory tests that is available in our lab is for academic research interest.

In summary, we present a case of left para-aortic PGL coexisting with an ipsilateral aldosterone-producing adenoma presenting as a left para-aortic tumor associated with bilateral adrenal tumors. The rare combination and unprecedented presentation make the differential diagnosis complicated and challenging, including both the confirmation of the great mimick PGL and the distinction between unilateral and bilateral hyperaldosteronism. The preparation with the alpha blocker before adrenal venous sampling and operation afterward in this setting is also worth of emphasis.

Abbreviations
ACTH: Adrenocorticotropic hormone; ARR : Aldosterone renin ratio; MIBG: Metaiodobenzylguanidine; ODST: Overnight dexamethasone suppression test; PGL: Paraganglioma; VMA: Vanillylmandelic acid.

Acknowledgements
Not applicable.

Authors’ contributions
YCH reviewed the literature, collected data, drafted the manuscript, and reviewed and revised the manuscript for submission. CHL and CYC cojoined the operation, reviewed the literature, and analyzed the evaluation data. CJH planned and performed the preoperative assessment, the operation, and the postoperative follow-up, provided the idea of the study, and supervised the manuscript writing. All authors read and approved the final manuscript.

Funding
No funding was obtained for this study.

Availability of data and materials
Clinical data from the corresponding author will be available upon request.

Declarations
Ethics approval and consent to participate
The patient agreed to participate in this study. Informed consent was obtained from the patient prior to the study.

Consent for publication
Written informed consent was obtained from the patient for publication of this case report and any accompanying images. A copy of the written consent is available for review by the Editor of this journal.

Competing interests
All authors certify that they have no competing interests to declare that they are relevant to the content of this article.

Author details
1Department of Obstetrics and Gynecology, College of Medicine, National Cheng Kung University Hospital, National Cheng Kung University, No. 138, Sheng-Li Road, Tainan, Taiwan. 2Department of Surgery, College of Medicine, National Cheng Kung University Hospital, National Cheng Kung University, No. 138, Sheng-Li Road, Tainan, Taiwan.

Received: 15 May 2022 Accepted: 18 October 2022 Published online: 12 November 2022

References
1. Kayser SC, Dekkers T, Groenewoud HJ, van der Wilt GJ, Carel Bakx J, van der Wel MC, Hermsus AR, Lenders JW, Deinum J. Study heterogeneity and estimation of prevalence of primary aldosteronism: a systematic review and meta-regression analysis. J Clin Endocrinol Metab. 2016;101:2826–35. https://doi.org/10.1210/jc.2016-1472.
2. Mattsson C, Young WF, Jr. Primary aldosteronism: diagnostic and treatment strategies. Nat Clin Pract Nephrol. 2019;2,198–208; quiz, 191 p following 230.(2006). https://doi.org/10.1038/nccnep10151.
3. Patrova J, Jarocka I, Wahrenberg H, Falhammer H. Clinical outcomes in adrenal incidentaloma: experience from one center. Endocr Pract. 2015;21:870–7. https://doi.org/10.14155/ep15618.07.
4. Pasternak JD, Seib CD, Seiser N, Tyrell JB, Liu C, Cosco RM, Giosell JE, Shen WT, Suh I, Duh QY. Differences between bilateral adrenal incidentalomas and unilateral lesions. JAMA Surg. 2015;150:974–8. https://doi.org/10.1001/jamasurg.2015.1683.
5. Aono D, Kometani M, Karashima S, Usukura M, Gondo Y, Hashimoto A, Demura M, Furukawa K, Takeda Y, Kawashishi M, Yoneda T. Primary aldo‑ steronism subtype discordance between computed tomography and adrenal venous sampling. Hypertens Res. 2019;42:1942–50. https://doi. org/10.1038/s41440‑019‑03110‑y.
6. Rossi GP. Update in adrenal venous sampling for primary aldosteronism. Curr Opin Endocrinol Diabetes Obstes. 2018;25:160–71. https://doi.org/10.1097/med.0000000000000407.
7. Williams TA, Reincke M. Management of endocrine disease: diagnosis and management of primary aldosteronism: the Endocrine Society guideline 2016 revisited. Eur J Endocrinol. 2018;179:R19–R29. https://doi.org/10.1530/eje‑17‑0990.
8. Rossi GP, Auchus RJ, Brown M, Lenders JW, Naruse M, Plouin PF, Satoh F, Young WF Jr. An expert consensus statement on use of adrenal vein sampling for the subtyping of primary aldosteronism. Hypertension. 2016;63:151–60. https://doi.org/10.1161/hypertensionaha.113.02097.
9. Neumann HPH, Young WF, Eng C. Pheochromocytoma and Paraganglioma. N Engl J Med. 2019;381:552–65. https://doi.org/10.1056/NEJMra1806651.
10. Berends AWA, Buitenwerf E, de Krijger RR, Veeger N, van der Horst‑Schrijvers ANA, Links TP, Kerstens MN. Incidence of pheochromocytoma and sympathetic paraganglioma in the Netherlands: a nationwide study and systematic review. Eur J Intern Med. 2018;51:668–73. https://doi.org/10.1016/j.ejim.2018.01.015.
11. Patel D, Phay JE, Yen TWF, Dickson PW, Wang TS, Garcia R, Yang AD, Solórzano CC, Kim LT. Update on Pheochromocytoma and Paraganglioma from the SSO Endocrine/Head and Neck Disease-Site Work Group. Part 1 of 2: Advances in Pathogenesis and Diagnosis of Pheochromocytoma and Paraganglioma. Annals of Surgical Oncology. 2020;27:1329–37. https://doi.org/10.1245/s10434‑020‑08220‑3.
12. Yucha C, Blakeman N. Pheochromocytoma. The great mimic. Cancer Nurs. 1991;14:136–40.
13. Aygun N, Uludag M. Pheochromocytoma and Paraganglioma. From Clinical Findings to Diagnosis. Sesi Efal Hastan Tip Bul. 2020;54:271–80. https://doi.org/10.14744/semab.2020.14826.
14. Hwang WR, Ma WY, Tso AL, Pan CC, Chang YH, Lin HD. Pheochromocy‑ toma and adrenocortical adenoma in the same gland. J Chin Med Assoc. 2007;70:289–93. https://doi.org/10.1016/j.jcma.2007.01.007.
15. Lo CY, Lam KY, Wat MS, Lam KS. Adrenal pheochromocytoma remains a frequently overlooked diagnosis. Am J Surg. 2000;179:212–5. https://doi.org/10.1016/s0002‑9610(00)00229‑8.
16. Kirkendall WM, Liechty RO, Culp DA. Diagnosis and treatment of patients with pheochromocytoma, experiences at university hospitals from 1941–1964. Arch Intern Med. 1965;115:529–36. https://doi.org/10.1001/archinte.1965.03860170014004.
17. Charles L, Triscott J, Dobbs B. Secondary hypertension: discovering the underlying cause. Am Fam Physician. 2017;96:453–61.
18. Hasassini ME, Pandian TK, Bobr AA, Bancos L, Young WF Jr, Richards ML, Farley DR, Thompson GB, McKenzie TJ. Pheochromocytoma with
Synchronous Ipsilateral Adrenal Cortical Adenoma. World J Surg. 2017;41:3147–53. https://doi.org/10.1007/s00268-017-4110-8.

19. Ohya Y, Sakata S, Miyata E, Igiuchi A, Momoseki S, Tsushitachi T. Case report: coexistence of pheochromocytoma and bilateral aldosterone-producing adenomas in a 36-year-old woman. J Hum Hypertens. 2010;24:555–7. https://doi.org/10.1038/jhh.2010.30.

20. Sakamoto N, Tojo K, Saito T, Fujimoto K, Isaka T, Tajima N, Ikeda K, Yamada H, Furuta N, Sasano H. Coexistence of aldosterone-producing adenocortical adenoma and pheochromocytoma in an ipsilateral adrenal gland. Endocr J. 2009;56:213–9. https://doi.org/10.1507/endocrj.08081-196.

21. Miyazawa K, Kiyokawa Y, Nakano S, Kobayashi Y, Suzuki K, Tsugawa R, Uchida K. Hypertension Due to Coexisting Pheochromocytoma and Aldosterone-Producing Adrenal Cortical Adenoma. Am J Nephrol. 1998;18:547–50. https://doi.org/10.1159/000013340.

22. Tan GH, Carney JA, Grant CS, Young WF. Jr. Coexistence of bilateral adrenal pheochromocytoma and idiopathic hyperaldosteronism. Clin Endocrinol (Oxf). 1996;44:603–9. https://doi.org/10.1111/j.1365-2265.1996.700390.x.

23. Gordon RD, Bachmann AW, Klemm SA, Tunn TJ, Stowasser M, Storie WJ, Rutherford JC. An association of primary aldosteronism and adrenal-secreting pheochromocytoma. Clin Exp Pharmacol Physiol. 1994;21:219–22. https://doi.org/10.1111/j.1440-1614.1994.tb02500.x.

24. Wajiki M, Ogasawara A, Fukui J, Komiyama Y, Yamada T, Maruyama Y. Coexistence of aldosteronoma and pheochromocytoma in an adrenal gland. J Surg Oncol. 1985;28:75–8. https://doi.org/10.1002/jso.2890280118.

25. Mao JJ, Baker JE, Rainey WE, Young WF, Jr. Bancos I. Concomitant Pheochromocytoma and Primary Aldosteronism: a case series and literature review. J Endocr Soc. 2021;5:bvab107. https://doi.org/10.1210/jendos/bvab107.

26. Park GE, Cho YY, Hong YS, Kang SH, Lee KH, Lee HW, Kim JH. A functioning adenocortical adenoma and pheochromocytoma in the same adrenal gland: two discrete adrenal incidentals. Korean J Intern Med. 2015;30:114–7. https://doi.org/10.3904/kjem.2015.30.1.114.

27. Wolf A, Willenberg HS, Cupisti K, Schott M, Geddert H, Raiffe A, Bornstein SR, Scherbaum WA, Knoefel WT. Adrenal pheochromocytoma with contralateral cortisol-producing adrenal adenoma: diagnostic and therapeutic management. Horm Metab Res. 2005;37:391–5. https://doi.org/10.1055/s-2005-780159.

28. Inoue J, Oishi S, Naoki S, Umeda T, Sato T. Pheochromocytoma associated with adrenocortical adenoma: case report and literature review. Endocrinol Jpn. 1986;33:67–74. https://doi.org/10.1507/endocrj/v954.3367.5.

29. Sparagana M, Feldman JM, Molinarz Z. An unusual pheochromocytoma associated with an androgen secreting adrenocortical adenoma. Evaluation of its polypeptide hormone, catecholamine, and enzyme characteristics. Cancer. 1987;60:223–31. https://doi.org/10.1002/1097-0214(19870715)60:2<223::aid-cnrcr280600218h3e3.0.co;2-j.

30. Cestesa D, Petralamia L, Serra V, Giustini S, Divona L, Salvestrini N. Cestesa D. Cessation of adrenocortical tumor coexisted with paragangliomas. Endocr J. 2001;48:499–502.

31. Bensghir M, Elwali A, Lalaoui SJ, Kamili ND, Alaoui H, Laoutid J, Azendour H, Balkhi H, Haimeur C, Atmani M: Management of undiagnosed pheochromocytoma or Sympathetic Paraganglioma. J Clin Endocrinol Metab. 2020;105:7330.0016. https://doi.org/10.1210/clinem/dgaa441.

Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.